<SEC-DOCUMENT>0001183740-22-000063.txt : 20220314
<SEC-HEADER>0001183740-22-000063.hdr.sgml : 20220314
<ACCEPTANCE-DATETIME>20220314160831
ACCESSION NUMBER:		0001183740-22-000063
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220314
FILED AS OF DATE:		20220314
DATE AS OF CHANGE:		20220314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRIGHT MINDS BIOSCIENCES INC.
		CENTRAL INDEX KEY:			0001827401
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40997
		FILM NUMBER:		22736622

	BUSINESS ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
		BUSINESS PHONE:		6474072515

	MAIL ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k-20220314drug.htm
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2021 [PPXY7CNC5JSVVFDLV1AJ]. www.edgarsuite.com -->
<HEAD>
<TITLE>UNITED STATES</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:64.8pt;width:482.4pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>UNITED STATES</B><BR><B>SECURITIES AND EXCHANGE COMMISSION</B><BR><B>Washington, D.C. &nbsp;20549</B></P>
<P align=center style='font:14pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>FORM 6-K</B></P>
<P align=center style='font:12pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>For the month of <B>March 2022</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Commission File No. <B>001-40997</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><FONT style='font-size:13pt;border-bottom:1px solid #000000'><B>BRIGHT MINDS BIOSCIENCES INC.</B></FONT><BR>(Translation of registrant's name into English)</P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>19 Vestry Street,</B><BR><FONT style='border-bottom:1px solid #000000'><B>New York, NY &nbsp;10013</B></FONT><BR>(Address of principal executive office)</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F</P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>Form 20-F</B>&#160;&#160;<B>[ X ]</B> &nbsp;Form 40-F<B>&#160;&#160;[ &nbsp;]</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) &#160;[ &nbsp;]</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) &#160;[ &nbsp;]</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0;background-color:#FFFFFF'><A name=_DV_M0 /><B>SUBMITTED HEREWITH</B></P>
<TABLE align=center style=border-collapse:collapse;width:475.45pt><TR><TD valign=top style=width:56.95pt><P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:5.4pt;color:#000000'><FONT style='border-bottom:1px solid #000000'><B>Exhibits</B></FONT></P>
</TD><TD valign=top style=width:418.5pt><P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:4.5pt;margin-right:7.65pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:56.95pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt;margin-left:5.4pt;color:#000000'>99.1</P>
</TD><TD valign=top style=width:418.5pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt;margin-left:2.6pt;margin-right:1.95pt;color:#000000'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><A href=ex991-20220314drug.htm style=text-decoration:none>News Release dated March </A><A href=ex991-20220314drug.htm style=text-decoration:none>14</A><A href=ex991-20220314drug.htm style=text-decoration:none>, 2022</A></FONT></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
</DIV>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>SIGNATURE</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:216pt'><B>BRIGHT MINDS BIOSCIENCES INC.</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:216pt'><I>/s/ Ryan Cheung</I><BR>__________________________<BR>Ryan Cheung<BR>Chief Financial Officer</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Date:  March 14, 2022</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-20220314drug.htm
<DESCRIPTION>NEWS RELEASE
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2021 [PPXY7CNC5JSVVFDLV1AJ]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt'><FONT style='font-family:Times New Roman'><IMG src=ex99120220314drug_1.jpg width=113 height=88></FONT>&nbsp;</P>
<P style='font:14pt Times New Roman;margin-top:0pt;margin-bottom:8pt'><B>For Immediate Release</B></P>
<P align=center style='font:14pt Times New Roman;margin-top:0pt;margin-bottom:8pt'><B>Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial</B></P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>Vancouver, BC &#8211;&nbsp;March 14, 2022 &#8211;&nbsp;Bright Minds Biosciences (&#8220;Bright Minds,&#8221; &#8220;BMB&#8221; or the &#8220;Company&#8221;) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the successful completion of 28-day repeat-dose toxicity studies for its lead product, BMB-101. Importantly, there were no major toxicological findings after twice daily oral administration of BMB-101 throughout the study period. The studies were conducted by the Company&#8217;s contract research partner, ITR Laboratories Canada in Baie d&#8217;Urf<FONT style='font-family:Times New Roman'>&#233;</FONT>, Qu<FONT style='font-family:Times New Roman'>&#233;</FONT>bec, Canada.</P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>Dr. Revati Shreeniwas, Bright Minds&#8217; Chief Medical Officer, stated, &#8220;Dravet Syndrome, a severe form of epilepsy characterized by frequent, prolonged seizures, is a terribly debilitating disease and, unfortunately, remains an area of high unmet medical need. We&#8217;re encouraged and hopeful that BMB-101 will provide a new and effective approach to its treatment. These data, generated in our 28-day toxicology studies, provide further support for advancing our clinical program,&#8221; concluded Dr. Shreeniwas.</P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>Repeat-dose oral toxicity studies were conducted in mice and dogs. These Good Laboratory Practice (GLP) compliant studies found that BMB-101, at doses up to 40 and 30 mg/kg/day in mice and dogs, respectively, were well tolerated at all dose levels. These data provide new information on a lack of major toxic effects after 28 days, including a lack of any effect to target organs. A no-observed-adverse-effect level (NOAEL) was identified in both species, which will be used in selecting starting dose levels and for establishing safety criteria for human exposure.</P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>&#8220;We are delighted to have completed this important milestone, which is pivotal for supporting our forthcoming first-in-human clinical trial, currently expected to begin in 2Q22,&#8221; said Ian McDonald, Bright Minds&#8217; Chief Executive Officer. &#8220;We have now officially entered the clinical development stage for our lead product, BMB-101, which represents an exciting new chapter for the Company and, hopefully, therapeutic alternative for patients suffering from Dravet Syndrome.&#8221;</P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000'>&nbsp;</P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt'><B>About BMB-101</B></P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>BMB-101, a 5-HT<SUB>2C</SUB> selective and biased agonist, has demonstrated compelling activity in a host of <I>in-vitro </I>and <I>in-vivo </I>non-clinical tests. Compared to Locaserin, BMB-101 exhibits strong Gq signaling coupled with minimal beta arrestin recruitment. Mechanistically, Serotonin (5- </P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>Hydroxytryptamine, 5-HT) is a monoamine neurotransmitter widely expressed in the central nervous system, and drugs modulating 5-HT have made a major impact in mental health disorders. Central 5-HT systems have long been associated with the control of ingestive behavior and the modulation of behavioral effects of psychostimulants, opioids, alcohol and nicotine. Over the past decade, the various 5-HT receptor subtypes have been cloned and characterized. Results of clinical trials and animal studies indicate that 5-HT<SUB>2C</SUB> up receptor agonists may have therapeutic potential in the treatment of addiction by decreasing the intake of opioids as well as impulsive behavior that can escalate compulsive drug use.</P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>&nbsp;</P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt'><B>About Dravet Syndrome</B></P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>Dravet syndrome is an epilepsy syndrome that begins in infancy or early childhood and can include a spectrum of symptoms ranging from mild to severe. Children with Dravet initially show focal (confined to one area) or generalized (throughout the brain) convulsive seizures that start before 15 months of age (often before age one). These initial seizures are often prolonged and involve half of the body, with subsequent seizures that may switch to the other side of the body. These initial seizures are frequently provoked by exposure to increased temperatures or temperature changes, such as getting out of a bath. Other seizure types emerge after 12 months of age and can be quite varied. Status epilepticus &#8211;&nbsp;a state of continuous seizure requiring emergency medical care &#8211;&nbsp;may occur frequently in these children, particularly in the first five years of life. Dravet syndrome affects an estimated 1:15,700 individuals in the U.S., or 0.0064% of the population (Wu 2015). Approximately 80-90% of those, or 1:20,900 individuals, have both an SCN1A mutation and a clinical diagnosis of DS. This represents an estimated 0.17% of all epilepsies. As an area of high, unmet medical need, there currently exist only three FDA-approved medications for the treatment of DS: (1) Fintepla&#174; (fenfluramine), which has a black-box label; (2) Diacomit&#174; (stiripentol) and (3) Epidolex&#174; (cannabidiol).</P>
<P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>&nbsp;</P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt'><B>About Bright Minds</B></P>
<P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds&#8217; drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:12pt Times New Roman;margin:0'><B>Investor Contacts:</B></P>
<P style='font:12pt Times New Roman;margin:0'>Lisa Wilson</P>
<P style='font:12pt Times New Roman;margin:0'>In-Site Communications, Inc.</P>
<P style='font:12pt Times New Roman;margin:0'>489 Fifth Avenue, 29th Floor</P>
<P style='font:12pt Times New Roman;margin:0'>New York, NY 10017</P>
<P style='font:12pt Times New Roman;margin:0'>E: <FONT style='color:#0000FF;border-bottom:1px solid #0000FF'>lwilson@insitecony.com</FONT></P>
<P style='font:12pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:12pt Times New Roman;margin:0;color:#7A7A7A;background-color:#FFFFFF'>Josh Blacher</P>
<P style='font:12pt Times New Roman;margin:0;color:#7A7A7A;background-color:#FFFFFF'>Vice President, Corporate Development</P>
<P style='font:12pt Times New Roman;margin:0;color:#7A7A7A;background-color:#FFFFFF'>Bright Minds Biosciences, Inc.</P>
<P style='font:12pt Times New Roman;margin:0;color:#7A7A7A;background-color:#FFFFFF'>19 Vestry Street</P>
<P style='font:12pt Times New Roman;margin:0;color:#7A7A7A;background-color:#FFFFFF'>New York, NY 10013</P>
<P style='font:12pt Times New Roman;margin:0;color:#7A7A7A;background-color:#FFFFFF'>E:&#160;<FONT style='border-bottom:1px solid #7A7A7A'><B>josh@brightmindsbio.com</B></FONT></P>
<P style='font:12pt Times New Roman;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99120220314drug_1.jpg
<TEXT>
begin 644 ex99120220314drug_1.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< '<# 2(  A$! Q$!_\0
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MGZW=36T8N!*B(5&W[Q)]ZTK/PYX;M_BVJ6VFV,5Q/HKRWEFD:LD;^;'M;&,
MG+#C&<9KRNY^*.NV^G^&-%TK2M3M=8TME>>%E8"Z&WE3&!G:>3TX%:=A\3-/
M@^)U[KUCX1UC^T+BR-O>62 ,V\,A$F,9' P>/3WH T-)M](^'WP^L_$D>BVN
MI:YK5\886N -D6]VVC./E4*O..23Z=-*_P!$U2Z\>^$-3UGPOH>GQ&Z:WGDM
M)%E-P[1N1D;1\H"GKDY[UPOA'XC!]*NO".N^%9]=TP2O+%!"A:: %R2"/8GK
MD$9Q6JGQ0AN;W0['PWX,OET;0[K[0T,6Z27<5D4+QD*,NQY))Q0!V6G?"NYM
MOC#<^)IO[*?1Y&D*V@&6 ,>T?)MV]>>M5/!_B6SOOB9J?@N3PYI?D6UQ=L+K
MR5+G$C$#&,=\?05YM%X[DT+XPW'B^_T;4(()C(RV<WR/\R;>XQ[TG@[Q?-#\
M6-4\5V6@:CJ$=PT[_9;5"[H)&R,X!H J?%'QE'K^I2Z1'H=CIZZ9>S1B6V7#
M2@$KSQ[9KSRM3Q')-/XEU.YGM)[1[BZDF\B=2KH&8L 0?K670 4444 %%%%
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
